REVIEW

LSD1, a double-edged sword, confers dynamic chromatin regulation but commonly promotes aberrant cell growth

[version 1; peer review: 2 approved]

Meghan M Kozub\textsuperscript{1}, Ryan M Carr\textsuperscript{2}, Gwen L Lomberk\textsuperscript{3}, Martin E Fernandez-Zapico\textsuperscript{2}

\textsuperscript{1}Genomics Laboratories, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
\textsuperscript{2}Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, USA
\textsuperscript{3}Division of Research, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA

Abstract
Histone-modifying enzymes play a critical role in chromatin remodeling and are essential for influencing several genome processes such as gene expression and DNA repair, replication, and recombination. The discovery of lysine-specific demethylase 1 (LSD1), the first identified histone demethylase, dramatically revolutionized research in the field of epigenetics. LSD1 plays a pivotal role in a wide range of biological operations, including development, cellular differentiation, embryonic pluripotency, and disease (for example, cancer). This mini-review focuses on the role of LSD1 in chromatin regulatory complexes, its involvement in epigenetic changes throughout development, and its importance in physiological and pathological processes.

Keywords
LSD1, KDM1a, histone demethylation, epigenetics, cancer

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. Barbara Majello, University of Naples
   Federico II, Naples, Italy
2. Philip Cole, Johns Hopkins University School of Medicine, Baltimore, USA

Any comments on the article can be found at the end of the article.
Introduction

Within the nuclei of all eukaryotic cells, DNA is highly compacted via interactions with histones and numerous other proteins to form chromatin. Histones are involved with supercoiling of DNA and are subjected to post-translation modifications (PTMs). Diverse covalent modifications to histones control the structure and dynamics of chromatin and regulate access to DNA, ultimately altering gene expression. Multiple biochemical moieties can be covalently added to specific amino acids on the N-terminus of the histone, or “histone tail”1,2. The sequence of histone tail modifications, or “histone code”, influences transcription and other processes, including DNA repair, replication, and recombination3.

Histone PTMs were historically thought to be irreversible until the discovery of enzymes catalyzing the addition and removal of methyl groups to lysine and arginine residues on histone tails4. Two evolutionarily conserved families of histone demethylases that recognize H3K4me as a substrate have been identified: lysine-specific demethylases (LSDs) and Jumonji C demethylases (JMJCs)5,6. LSD enzymes demethylate mono- and di-methyl groups of lysine residues and some non-histone targets. JMJCs belong to the dioxygenase superfamily involved in deoxygenation reactions dependent on ferrous iron and α-ketoglutarate allowing demethylation of trimethylated lysine residues6,7. Lysine-specific histone demethylase I (LSD1) was first described in 2004, inspiring the hypothesis that histone modification is a highly dynamic process8.

This review focuses on LSD1 (also known as KDM1a) and its role in various physiological and pathological processes. LSD1 acts on histone H3 as a transcription co-repressor through demethylation of lysine 4 (H3K4) or as a transcription co-activator through demethylation of lysine 9 (H3K9)9,10. The enzyme is essential in the control of wide-ranging biological processes, including cell proliferation11,12, chromosome segregation12, hematopoiesis13, spermatogenesis14, adipogenesis15, stem cell pluripotency16, and embryonic development14. LSD1 can act as an oncogene, and its overexpression promotes cancer cell proliferation, migration, and invasion10,11.

LSD1 complex with regulatory proteins to facilitate histone demethylation

LSD1 consists of three structural domains: N-terminal SWIRM domain, C-terminal flavin adenine dinucleotide (FAD)-binding amine oxidase domain, and the tower domain. The SWIRM domain consists of proteins Swi3, Rsc8, and Moira. Through hydrophobic interactions, the FAD domain closely associated with SWIRM, forming a spherical core. Extending from the core is the tower domain forming an elongated helix-turn-helix motif.

Frequently, LSD1 is found to be associated with a transcriptional co-repressor protein (CoREST) and histone deacetylase (HDAC) 1/2 to form a complex. Interaction with CoREST is necessary for LSD1 H3K4 demethylation12-22. Association of the FAD domain with CoREST-histone ternary complex results in conformational change, permitting association with the N-terminal H3 tail12,23. With H3K4 in close propinquity to the FAD domain, oxidative demethylation results in increased affinity for LSD113,23-27. LSD1 requires the first 20 N-terminal amino acids of the histone tail for substrate recognition and interaction18,29. The specific amino-acid sequence allows LSD1 to sense the epigenetic messages encoded within histone tail and efficiently carry out demethylation. The presence of other epigenetic marks on H3 has the potential to affect the enzymatic activity of LSD1, suggesting a regulatory role for the H3 tail bereft of all other epigenetic modifications upon LSD1 activity29,30.

Within the aforementioned complex, LSD1 demethylates mono- and di-methylated H3K412,23,30,31. Earlier studies identified REST as a long-term repressor of neuronal genes in non-neuronal cells13,32-34. This was determined to be mediated through the recruitment of the LSD1-CoREST-HDAC complex, thus allowing lysine deacetylation of H3 and H4 in addition to demethylation of H3K435. In other investigations, RNA interference (RNAi)-mediated knockdown of LSD1 resulted in H3K4 methylation mark recurrence in proximity to REST target promoters, confirming this regulatory function36. While methylation of H3K4 activates transcription, demethylation by LSD1 confers transcriptional repression32. LSD1 also serves as a transcriptional activator. For example, androgen receptor (AR) activation of its target genes is dependent upon LSD1-mediated H3K9 demethylation37. Following hormone treatment, AR and LSD1 co-localize to promoters, resulting in H3K9 demethylation without changing H3K4 methylation status38. As expected, LSD1 knockdown resulted in reduced activation of AR-responsive promoters39. Taken together, the above findings showed the potential of LSD1 as a transcriptional repressor or activator through dynamic and selective H3K4 demethylation and H3K9 demethylation, respectively (Figure 1).

LSD1 contributes to broad, dynamic gene regulation through histone demethylation

Under physiological conditions, LSD1 has been found to have several functions ranging from regulation of hormone receptor-mediated transcription, appropriate hematopoietic stem cell differentiation, and cell cycle control. Estrogen receptor (ER)-mediated transcription is driven by LSD1-mediated H3K9 demethylation40. Following hormone treatment, AR and LSD1 co-localize to promoters, resulting in H3K9 demethylation without changing H3K4 methylation status41. As expected, LSD1 knockdown resulted in reduced activation of AR-responsive promoters42,43. Taken together, the above findings showed the potential of LSD1 as a transcriptional repressor or activator through dynamic and selective H3K4 demethylation and LSD1-mediated transcriptional repression via histone demethylation and through DNA damage-induced chromatin remodeling.

In addition to driving hormone receptor-mediated gene expression, LSD1 plays a critical role in hematopoiesis. LSD1 is dynamically involved in hematopoietic differentiation through cooperation with growth factor–independent (GFI) proteins. GFI proteins promote expression of lineage-specific genes, and LSD1 specifically interacts with GFI1B binding sites. In mouse models, RNAi depletion of LSD1 impairs both erythrocyte and megakaryocyte differentiation, but activated spontaneous granulocyte differentiation. Therefore, actions of LSD1 may be lineage-specific34. However, alternative
models have revealed competing findings that LSD1 is necessary for terminal differentiation of erythroid, megakaryocytic, and granulocytic lineages. Although its specific role is not fully characterized, LSD1 was found to regulate promoters and enhancers of genes associated with hematopoietic stem cells and was critical for terminal differentiation of mature hematopoietic cells as LSD1 knockout resulted in severe pancytopenia.

Finally, LSD1 biological functions are associated with the regulation of the methylation status of non-histone proteins. Studies demonstrate the relationship between retinoblastoma gene (RB1) and LSD1 in cell cycle control. Overexpression of RB1, the first identified tumor suppressor, causes cells to undergo arrest in the G1 phase of the cell cycle, and, as expected, abrogation of RB1 accelerates G1 transition. Phosphorylation is a key mechanism by which RB1 is regulated. Dephosphorylation is mediated by myosin phosphatase, which promotes cell cycle arrest. Interestingly, myosin phosphatase target subunit 1 (MYPT1) was identified as a novel substrate of LSD1. Methylation of MYPT1 is mediated by LSD1, preventing dephosphorylation of RB1 and ultimately promoting cell cycle progression. Given these diverse functions, one can see how altered LSD1 activity could contribute significantly to normal homeostasis and pathology such as malignancy.

Aberrant LSD1 activity suppresses cell cycle regulators and promotes tumor growth

Given the aforementioned role of LSD1 in cell cycle regulation, one may hypothesize that it could serve as an oncogene in the context of malignant transformation. LSD1 was first found to be overexpressed in neuroblastoma, correlating with poor differentiation. Overexpression of LSD1 has been documented in many solid tumors and is correlated with aggressive clinicopathological features and poor patient outcomes. Both in vitro and in vivo models have demonstrated overexpression of LSD1 correlating with significant chromatin modifications and malignant transformation. Both pharmacological inhibition and genetic depletion of LSD1 have been shown to inhibit cancer cell proliferation, differentiation, invasion, and metastasis in animal models. Thus, LSD1 has been confirmed to be an important oncogenic driver, a potential biomarker indicative of poor prognosis, and a potential therapeutic target. There are several forms of malignancy that have been shown to have aberrant LSD1 activity.
First, LSD1 is critical in the process of terminal differentiation in hematopoiesis, and abnormal LSD1 activity is correlated with a variety of myeloproliferative disorders\textsuperscript{11,30,31,33}. Many studies propose LSD1 as a prospective treatment target for acute myeloid leukemia (AML). AML is a heterogenous hematopoietic malignancy characterized by the accumulation of incompletely differentiated progenitor cells (blasts) in the bone marrow, causing suppression of normal hematopoiesis\textsuperscript{34}. LSD1 is a required constituent of a mixed-lineage leukemia (MLL) super complex associated with active transcription sites\textsuperscript{64}. Abrogation of LSD1 results in heightened rates of apoptosis and impaired leukemogenicity in an MLL-AF9 mouse model\textsuperscript{38}. In acute promyelocytic leukemia, all-trans retinoic acid can induce differentiation of leukemic cells whereas AML is not responsive. However, inhibition of LSD1 activity in AML models results in increased H3K4me2 at myeloid differentiation-associated genes, resulting in increased responsiveness to all-trans retinoic acid\textsuperscript{40}. These data support the importance of LSD1-mediated alteration of the leukemic epigenome in pathogenesis and demonstrate how the enzyme could serve as a therapeutic target in AML.

LSD1 is also dysregulated in solid tumors, including colorectal carcinoma. Increased activity in colon cancer is associated with increased metastatic potential\textsuperscript{51}. Higher expression of LSD1 and low expression of CDH-1 (E-cadherin) in colorectal cancer were associated with higher tumor-node-metastasis staging and thus poorer prognosis\textsuperscript{68}. Knockdown of LSD1 results in CDH-1 upregulation and confers invasiveness. LSD1 regulates the CDH-1 promoter and demethylation of H3K4me2 causes downregulation of CDH-1 expression\textsuperscript{69}.

Squamous cell carcinoma (SCC) is also associated with elevated LSD1 activity. The most common genetic aberration in SCC of the lung, esophagus, and oral cavity is amplification of Sox2\textsuperscript{62}. Sox2 encodes a transcription factor important in embryonic stem cells with the ability to reprogram somatic cells into induced pluripotent stem cells. Elevated LSD1 levels are associated with amplified Sox2 expression in lung cancer. Cells from these patients are particularly sensitive to the LSD1 inhibitor, CB1007, whereas Sox2-negative cells are not\textsuperscript{64}. Subsequent chromatin immunoprecipitation (ChIP) sequencing revealed that LSD1 binds to the Sox2 gene and is enriched in the transcriptional regulator region, a known distant enhancer for Sox2 expression in breast cancer. LSD1 inhibition revealed that its activity is required for Sox2 expression. Inactivation results in increased global H3K9me1/me2 and H3K27me3 with formation of bivalent chromatin domains within the regulatory regions of Sox2 and cell cycle regulatory genes, leading to suppression of gene expression\textsuperscript{63}.

ER-negative breast cancer is a subtype of the common malignancy with relatively more rapid growth, loss of differentiation, and increased propensity for metastasis. Interestingly, LSD1 tends to be highly expressed in this form of breast cancer\textsuperscript{27}. LSD1 and HDAC closely interact and control the growth of breast cancer through aberrant gene silencing\textsuperscript{18}.

**Upregulation of LSD1 promotes epithelial-to-mesenchymal transition**

Aberrant LSD1 activity is extensively characterized in multiple cancers, but the mechanism by which it promotes cancer progression extends beyond suppression of cell cycle regulators. For example, through PTM of a notable non-histone protein, p53, LSD1 represses apoptosis. This is achieved through demethylation of K370me2. Whereas methylation at this site promotes association of p53 with co-activator 53BP1, LSD1 inhibits this interaction\textsuperscript{66}. A more thoroughly studied role of LSD1 is in the epithelial-to-mesenchymal transition, a critical process in cancer progression. Snail and Slug are key molecular mediators of epithelial-to-mesenchymal transition through direct repression of epithelial markers such as CDH-1. This is achieved through the SNAG domain of Snail, structurally resembling the histone H3 tail, recruiting LSD1 to epithelial gene promoters with formation of the Snail-LSD1-CoREST complex with subsequent demethylation of H3K4me2\textsuperscript{67,68}. In the specific case of neuroblastoma, MYCN has been correlated with poor prognosis. This is related to the co-localization of LSD1 and MYCN at the promoter of a key suppressor of metastasis, N-Myc downstream-regulated gene 1 (NDRG1), inhibiting its expression. Thus, elevated LSD1 is associated with lower NDRG1 expression and poor prognosis\textsuperscript{89}. Inhibition of enzymatic activity or abrogation of the SNAG-LSD1 interaction suppresses mesenchymal markers, decreasing cancer invasiveness\textsuperscript{70,71}. Promoting transition to a mesenchymal phenotype is opposed by acetylation of LSD1 by males absent on the first (MOF). In fact, MOF expression correlates with favorable prognosis in cancer\textsuperscript{71}.

In summary, there is an abundance of evidence for a role of LSD1 in the pathogenicity of a wide array of malignancies. Cancer is the consequence of complex and heterogeneous genetic alterations, and aberrant LSD1 activity can contribute to a malignant phenotype through extensive modifications of the epigenome. Therefore, therapeutic targeting of the demethylase may prove an effective strategy in reversing or attenuating more aggressive malignant phenotypes in many cancers.

**Conclusions**

This review has briefly summarized the current knowledge and research of LSD1, its expression patterns, recruitment mechanisms, chromatin remodeling, biochemical functions, molecular structure, and role in cancer. In the past several years, studies have elucidated the role that histone lysine demethylases play in epigenetic regulation. LSD1 was the first histone demethylase identified and catalyzes the oxidation of methylated H3K4 through an amine oxidation reaction. Furthermore, LSD1 can act on non-histone proteins. While LSD1 is critical in conferring the dynamic nature of epigenetic regulation through histone modification, imbalance in histone modification with excessive LSD1 activity is significantly associated with increased cellular growth and suppression of cell cycle regulatory proteins in a broad array of tissues. Thus, LSD1 represents a critical oncogene and potential therapeutic target. More is to be elucidated regarding the function of LSD1. Interestingly, Wang et al. reported that LSD1 inhibits the invasion of breast cancer cells in vitro but conversely suppresses breast cancer metastatic potential in vivo\textsuperscript{71}. These data suggest not only that LSD1 is multifunctional but also that its functions may be highly context-dependent. More extensive studies into the effects of these contexts on LSD1 function will be important to fully understand its role in cancer. A significant amount of research has been devoted to the development of a wide range of epigenetic therapies. Numerous questions still must be answered regarding
LSD1 if effective therapeutic strategies are to be developed. For example, what are the functions and interactions of other LSD1 domains, or does LSD interact with methyltransferases, and how are these relationships regulated? In regard to the development of further therapies, elucidation should be placed on the development of highly specific drugs for demethylase subtypes to better direct the desired epigenetic effect of the drug. This would help specifically discern enzyme subtype mechanism. Despite these challenges, LSD1 is clearly important in normal cellular functions and malignancy.

Competing interests
The authors declare that they have no competing interests.

References

1. Jennewein T, Allis CD: Translating the histone code. Science. 2001; 293(5532): 1074–80. PubMed Abstract | Publisher Full Text | F1000 Recommendation
2. Banister AJ, Kouzarides T: Regulation of chromatin by histone modifications. Cell Res. 2011; 21(3): 381–95. PubMed Abstract | Publisher Full Text | Free Full Text
3. Kouzarides T: Chromatin modifications and their function. Cell. 2007; 128(4): 693–705. PubMed Abstract | Publisher Full Text
4. Pedersen MT, Helin K: Histone demethylase LSD1 promotes cell cycle progression in cancer cells. Trends Cell Biol. 2010; 20(11): 662–71. PubMed Abstract | Publisher Full Text
5. Kisse RJ, Kallin EM, Zhang Y: JmjC-domain-containing proteins and histone demethylation, Nat Rev Genet. 2006; 7(9): 715–27. PubMed Abstract | Publisher Full Text
6. Chen X, Hu Y, Zhou DX: Epigenetic gene regulation by plant Jumonji group of histone demethylase, Biochim Biophys Acta. 2011; 1809(9): 421–6. PubMed Abstract | Publisher Full Text
7. Shi Y, Lan F, Matson C, et al.: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7): 941–53. PubMed Abstract | Publisher Full Text | F1000 Recommendation
8. “KDM1A Lysine Demethylase 1A [Homo Sapiens (human)]”, National Center for Biotechnology Information. U.S. National Library of Medicine, n.d. Web. 29 June 2016.
9. Metzger E, Wisemann M, Yin N, et al.: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005; 437(7057): 436–9. PubMed Abstract | Publisher Full Text | F1000 Recommendation
10. Scoumanne A, Chen X: The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 2007; 282(21): 15471–5. PubMed Abstract | Publisher Full Text
11. Hayami S, Kelly JD, Cho HS, et al.: Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011; 128(3): 574–86. PubMed Abstract | Publisher Full Text
12. Cho HS, Suzuki T, Dohmae N, et al.: Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011; 71(3): 655–60. PubMed Abstract | Publisher Full Text
13. Lu S, Bu W, Jiao H, et al.: LSD1 is required for chromosome segregation during mitosis. Eur J Cell Biol. 2010; 89(7): 557–63. PubMed Abstract | Publisher Full Text
14. Li Y, Deng C, Hu X, et al.: Dynamic interaction between TAL1 oncprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis. Oncogene. 2012; 31(48): 5007–18. PubMed Abstract | Publisher Full Text | Free Full Text
15. Godmann M, Auger V, Farraroni-Aguai V, et al.: Dynamic regulation of histone H3 methylation at lysine 4 in mammalian spermatogenesis. Biol Reprod. 2007; 77(5): 754–64. PubMed Abstract | Publisher Full Text
16. Musri MM, Carmona MC, Hanzu FA, et al.: Histone demethylase LSD1 regulates adipogenesis. J Biol Chem. 2010; 285(39): 30034–41. PubMed Abstract | Publisher Full Text | Free Full Text
17. Zhou H, Li W, Zhu S, et al.: Conversion of mouse epiblast stem cells to an earlier pluripotency state by small molecules. J Biol Chem. 2010; 285(39): 29676–80. PubMed Abstract | Publisher Full Text | Free Full Text
18. Foster CT, Dovey OM, Lezina L, et al.: Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. Mol Cell Biol. 2010; 30(20): 4851–63. PubMed Abstract | Publisher Full Text | Free Full Text
19. Ballas N, Battaglioli E, Atouf F, et al.: Regulation of neuronal traits by a novel transcriptional complex, Neuron. 2001; 31(3): 353–65. PubMed Abstract | Publisher Full Text
20. Shi Y, Sawada J, Sui G, et al.: Coordinated histone modifications mediated by a CIBP co-repressor complex. Nature. 2003; 422(6933): 735–8. PubMed Abstract | Publisher Full Text
21. Humphrey GW, Wang Y, Russanova VR, et al.: Stable histone deacetylation complexes distinguished by the presence of SANT domain proteins CoREST/ kispe071 and Ifta-L1. J Biol Chem. 2001; 276(41): 3817–24. PubMed Abstract | Publisher Full Text
22. You A, Tong JK, Grozinger CM, et al.: CoREST is an integral component of the CoREST-human histone deacetylation complex. Proc Natl Acad Sci U S A. 2001; 98(4): 1454–8. PubMed Abstract | Publisher Full Text | Free Full Text
23. Forneris F, Binda C, Adamo A, et al.: Structural basis of LSD1-CoREST selectivity in histone H3 recognition. J Biol Chem. 2007; 282(28): 20070–4. PubMed Abstract | Publisher Full Text | F1000 Recommendation
24. Yang M, Culham JC, Szwuczak LM, et al.: Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol. 2007; 14(6): 535–9. PubMed Abstract | Publisher Full Text
25. Yang M, Gocke CB, Luo X, et al.: Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol Cell. 2006; 23(3): 377–87. PubMed Abstract | Publisher Full Text | F1000 Recommendation
26. Stavropoulos P, Blobel G, Hoez A: Crystal structure and mechanism of human lysine-specific demethylase 1. Nat Struct Mol Biol. 2006; 13(7): 626–32. PubMed Abstract | Publisher Full Text | F1000 Recommendation
27. Chen Y, Yang Y, Wang F, et al.: Crystal structure of human histone lysine-specific demethylase 1 (LSD1), Proc Natl Acad Sci U S A. 2006; 103(38): 13956–61. PubMed Abstract | Publisher Full Text | Free Full Text
28. Forneris F, Binda C, Varonzi MA, et al.: Human histone demethylase LSD1 reads the histone code. J Biol Chem. 2005; 280(50): 41360–5. PubMed Abstract | Publisher Full Text
29. Forneris F, Binda C, Dall’Aglio A, et al.: A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1, J Biol Chem. 2006; 281(46): 35289–95. PubMed Abstract | Publisher Full Text
30. Shi YJ, Matson C, Lan F, et al.: Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005; 19(5): 857–64. PubMed Abstract | Publisher Full Text | F1000 Recommendation
31. Lee MG, Wynder C, Cooch N, et al.: An essential role for CoREST in...
nucleosomal histone 3 lysine 4 demethylation. Nature. 2008; 437(7057): 432–5.

32. "Bernstein BE, Kamal M, Lindblad-Toh K, et al.: Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2002; 109(2): 169–81.

33. "Ballas N, Grunseich C, Lu DD, et al.: REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell. 2005; 121(4): 645–57.

34. "Ooi L, Wood IC: LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol. 2011; 13(6): 652–9.

35. "Forneris F, Binda C, Vanoni MA: Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett. 2005; 579(10): 2203–7.

36. "Perillo B, Ombra MN, Bertoni A, et al.: DNA oxidation as triggered by H3K4me2 demethylation drives estrogen-induced gene expression. Science. 2008; 319(5860): 202–6.

37. "Hu Q, Kwon Y, Nunez E, et al.: Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci U S A. 2008; 105(49): 19199–204.

38. "Adamo A, Sesé B, Boue S, et al.: LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nature. 2011; 476(7358): 432–5.

39. "Lokken AA, Zeleznik-Le NJ: LSD1 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010; 5(1): e9860.

40. "Maier S, Wilbertz T, Braun M, et al.: SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol. 2011; 42(8): 1079–88.

41. "Kerenyi MA, Shao Z, Hsu YJ, et al.: Histone demethylation LSD1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. eLife. 2013; 2:e00363.

42. "Lee WH, Bookstein R, Hong F, et al.: Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987; 235(4794): 1394–9.

43. "Goodrich DW, Wang NP, Qian YW, et al.: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. 1991; 67(2): 293–302.

44. "Glasson M, Harlove E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002; 2(12): 910–7.

45. "Schulte HJ, Lim S, Schramm A, et al.: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastomas: implications for therapy. Cancer Res. 2009; 69(5): 2066–71.

46. "Amonte S, Lania L, Majello BL: The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim Biophys Acta. 2013; 1829(10): 981–91.

47. "Magerl C, Ellinger J, Braunschweig T, et al.: H3K4 demethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase ASH2 and the demethylase LSD1. Hum Pathol. 2010; 41(2): 181–9.

48. "Kim S, Jucker A, Becker A, et al.: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010; 31(3): 512–20.

49. "Bernini-Baiti IM, Machado I, Liambotis-Bosch A, et al.: Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012; 43(6): 1300–7.

50. "Lv T, Yuan D, Miao X, et al.: Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012; 7(4): e35065.

51. "Kaufman EC, Robinson BD, Downes MJ, et al.: Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD1A, in localized and advanced human bladder cancer. Mol Carcinog. 2011; 50(12): 931–44.

52. "Huang Y, Greene E, Murray Stewart T, et al.: Inhibition of lysine-specific demethylase 1 by polyamine analogues results in repression of aberrantly silenced genes. Proc Natl Acad Sci U S A. 2007; 104(19): 8023–8.

53. "Kahl P, Gullotti L, Heukamp LC, et al.: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006; 66(3): 11341–7.

54. "Harris WJ, Huang X, Lynch JT, et al.: The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012; 21(4): 472–87.

55. "Mould DP, McGonagle AE, Wiseman DH, et al.: Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med Res Rev. 2013; 33(6): 606–618.

56. "Singh AB, Sharma A, Smith JJ, et al.: Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology. 2011; 141(6): 2140–53.

57. "Jie D, Zhongmin Z, Guoging L, et al.: Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 2013; 58(6): 1581–9.

58. "Ding J, Zhang ZM, Xia Y, et al.: LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer. 2013; 109(4): 994–1003.

59. "Zhang X, Watanabe H, Mermod CH, et al.: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009; 41(11): 1238–42.

60. "Hussenet T, Dall S, Ei-Jæger, et al.: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010; 5(1): e9860.

61. "Maier S, Wilbertz T, Braun M, et al.: SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol. 2011; 42(8): 1079–88.

62. "Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012; 7(4): e35065.

63. "Kaufman EC, Robinson BD, Downes MJ, et al.: Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD1A, in localized and advanced human bladder cancer. Mol Carcinog. 2011; 50(12): 931–44.

64. "Huang Y, Greene E, Murray Stewart T, et al.: Inhibition of lysine-specific demethylase 1 by polyamine analogues results in repression of aberrantly silenced genes. Proc Natl Acad Sci U S A. 2007; 104(19): 8023–8.
Open Peer Review

Current Peer Review Status:  

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Philip Cole  
   Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, USA  
   Competing Interests: No competing interests were disclosed.

2. Barbara Majello  
   Department of Biology, University of Naples Federico II, Naples, Italy  
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com